383.62 0.00 (0.00%)
After hours: 5:15PM EST
|Bid||383.62 x 800|
|Ask||391.78 x 1100|
|Day's range||383.09 - 404.48|
|52-week range||196.78 - 555.77|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||86.21|
|Earnings date||28 Apr 2021 - 03 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||408.13|
Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.
Last month, U.S. Securities and Exchange Commission (SEC) filings revealed that Warren Buffett had made large purchases of Verizon and Chevron stock in the third and fourth quarter of 2020. Illumina (NASDAQ: ILMN), maker of genome sequencing machines, may not be the type of secure, stable company Buffett likes, but it is at the forefront of a revolution in medicine and has several traits that the magnate covets. In his 1995 shareholder letter, Buffett said that he looks for "economic castles protected by unbreachable moats."
Illumina (ILMN) closed the most recent trading day at $398.85, moving -0.19% from the previous trading session.